Spebrutinib besylate is under clinical development by Bristol-Myers Squibb and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Spebrutinib besylate’s likelihood of approval (LoA) and phase transition for Diffuse Large B-Cell Lymphoma took place on 13 Jun 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

In addition, the same event on 13 Jun 2022 increased Spebrutinib besylate’s LoA and PTSR for Follicular Lymphoma.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Spebrutinib besylate Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Spebrutinib besylate overview

Spebrutinib besylate (CC-292, AVL-292) is under development for the treatment of relapsed or refractory diffuse large B-cell lymphoma, small lymphocytic lymphoma and follicular lymphoma. The drug candidate is administered orally. The drug candidate targets Bruton’s tyrosine kinase (Btk). It was also under development for systemic lupus erythematosus (SLE), multiple myeloma-related bone disease, B-cell non-Hodgkin lymphoma, mantle cell lymphoma, relapsed/refractory B-cell lymphoma including Waldenstrom macroglobulinemia and rheumatoid arthritis.

Bristol-Myers Squibb overview

Bristol-Myers Squibb (BMS) is a specialty biopharmaceutical company that is engaged in discovery, development, licensing and manufacturing, marketing, distribution and sale of medicines and related medical products to patients with serious diseases. Its primary focus is on cancer, cardiovascular, immunology and fibrotic therapeutic projects. The company offers its products across the world to wholesalers, retail pharmacies, hospitals, medical professionals and government entities. BMS provides its products in the US, Europe, and Japan. The company conducts research to focus on the discovery and development of novel medicines that address serious diseases in areas of significant unmet medical need. BMS is headquartered in New York City, New York, the US.

Quick View Spebrutinib besylate LOA Data

Report Segments
  • Innovator
Drug Name
  • Spebrutinib besylate
Administration Pathway
  • Oral
Therapeutic Areas
  • Immunology
  • Musculoskeletal Disorders
  • Oncology
Key Developers
Highest Development Stage
  • Phase I

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.